Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
Chronic kidney disease (CKD) is a burden of morbidity and mortality. Increased protein
breakdown in skeletal muscle (wasting) and ectopic fat deposition are important determinants
of poor clinical outcome in patient with CKD. Insulin resistance plays a critical role in
skeletal muscle wasting and ectopic fat deposition. Glucagon-like peptide-1 receptor agonists
(GLP-1RA) decrease ectopic fat deposition in patients with type 2 diabetes, prediabetes,
obese and overweight subjects.
The influence of GLP-1RA on ectopic fat deposition in CKD patients in unknown. The
investigators' will test the hypothesis that GLP-1RA decreases intermuscular (ectopic) fat
deposition in patients with stage 3-4 CKD. The investigators' will do so by addressing the
following specific aims:
Specific Aim 1: To test the hypothesis that GLP-1RA decreases intermuscular fat deposition in
patients with stage 3-4 CKD.
Specific Aim 2: To test the hypothesis that GLP-1RA improves skeletal muscle mitochondrial
function in patients with stage 3-4 CKD.
Specific Aim 3: To test the hypothesis that GLP-1RA improves physical performance in patients
with stage 3-4 CKD.
Specific Aim 4: To test the safety and feasibility of 12 weeks of dulaglutide 1.5 mg/wk
administration as an adjunct therapy to the standard care of patients with stage 3-4 CKD.